Tag:
Adnexus Therapeutics
Latest Headlines
Latest Headlines
Bristol CEO touts successful biopharma blitz after big hep C play
Bristol-Myers Squibb ( $BMY ) mounted an enviable makeover from a diversified company to a biopharma force over the past several years, with the famed "String of Pearls" strategy advanced to buy
BMS pays $505M for Adnexus
Adnexus Therapeutics is abandoning its move to go public , opting for a buyout by Bristol-Myers Squibb that will net $430
Adnexus outlines $86M IPO to advance adnectins
With its lead therapy poised to begin mid-stage trials early next year, Adnexus Therapeutics has filed papers with the SEC for an IPO designed to raise $86.3 million. The company is developing
